Literature DB >> 7730666

Method for quantitation of IgG subclass antibodies in mouse serum by enzyme-linked immunosorbent assay.

R K Gupta1, G R Siber.   

Abstract

One of the methods for calibration of antigen specific antibodies in a serum involves parallel titration of known concentrations of purified normal immunoglobulins (Igs) and a specific antiserum. We evaluated the effect of three methods for capturing known concentrations of purified normal mouse Igs (IgG, IgG subclasses and IgM) on the anti-tetanus toxoid antibody concentrations assigned to a reference mouse serum: (1) direct coating, (2) capture by pre-coated anti-mouse IgG (Fc) specific antibodies, and (3) capture by pre-coated anti-mouse IgG (Fab) specific antibodies. Direct coating of purified Igs onto plastic was the least efficient and would greatly overestimate antigen specific antibody concentrations. Equivalent concentrations of purified IgG subclasses and IgM produced higher absorbances when captured by anti-Fab antibodies pre-coated on plates than by anti-Fc antibodies. As a consequence, the anti-Fc capture method resulted in the assignment of IgG1, IgG2a and IgG2b tetanus specific antibody concentrations which exceeded the total IgG1, IgG2a and IgG2b concentrations. Additionally, the sum of tetanus specific IgG subclass antibodies exceeded the tetanus specific IgG antibody concentration by > 2-fold. In contrast, the anti-Fab capture method resulted in 2-9-fold lower assigned tetanus antibody concentrations which did not exceed the total Ig concentrations. We conclude that when using enzyme-linked immunosorbent assays, parallel titration of purified normal Ig standards captured by anti-Fab antibodies is superior to anti-Fc capture or direct coating for calibrating antigen specific antibodies in a reference serum.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7730666     DOI: 10.1016/0022-1759(94)00331-p

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  5 in total

1.  Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague.

Authors:  R W Titball; A M Howells; P C Oyston; E D Williamson
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

2.  B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice.

Authors:  Daniel P Ankeny; Zhen Guan; Phillip G Popovich
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

3.  Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica Serovar Typhimurium flagellin.

Authors:  Monica Teixeira Andrade Leal; Ariane Guglielmi Ariza Camacho; Laís Helena Teixeira; Daniel Youssef Bargieri; Irene Silva Soares; Cibele Aparecida Tararam; Mauricio M Rodrigues
Journal:  Clin Vaccine Immunol       Date:  2013-07-17

4.  Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents.

Authors:  Lais H Teixeira; Cibele A Tararam; Marcio O Lasaro; Ariane G A Camacho; Jonatan Ersching; Monica T Leal; Sócrates Herrera; Oscar Bruna-Romero; Irene S Soares; Ruth S Nussenzweig; Hildegund C J Ertl; Victor Nussenzweig; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2013-12-09       Impact factor: 3.441

5.  Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge.

Authors:  Tarsila Mendes de Camargo; Elisângela Oliveira de Freitas; Alba Marina Gimenez; Luciana Chagas Lima; Karina de Almeida Caramico; Kátia Sanches Françoso; Oscar Bruna-Romero; Chiara Andolina; François Nosten; Laurent Rénia; Hildegund C J Ertl; Ruth S Nussenzweig; Victor Nussenzweig; Mauricio M Rodrigues; Arturo Reyes-Sandoval; Irene S Soares
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.